Design and Formulation of Once Daily Naproxen SustainedRelease Tablet Matrix from Methocel K 15M CR and Methocel K 100M CR Formulation of naproxen SR tablet matrix
Iranian Journal of Pharmaceutical Sciences,
Vol. 5 No. 4 (2009),
1 October 2009
,
Page 215-224
https://doi.org/10.22037/ijps.v5.41225
Abstract
The purpose of this work was to develop once daily sustained release (SR) matrix tablets of naproxen, an anti-inflammatory agent. The tablets were prepared by wet granulation method along with hydrophilic matrix materials like Methocel K 15M CR and Methocel K 100M CR. The granules were evaluated for bulk density, angle of repose, compressibility index, total porosity and drug content. The tablets subjected to thickness, diameter, weight variation test, drug content, hardness,friability, and in vitrorelease studies in buffer medium (pH, 7.4). The granules prepared either by Methocel K 15M CR or Methocel K 100M CR did not show satisfactory flow properties and compressibility, and had difficulty in sieving and individual in drug release. On the other hand, tablet matrix prepared along with Methocel K 15M CR and Mehtocel K 100 LVCR polymers of the proposed formulation F-8 showed desired drug release up to 24 h. All the formulations followed first order release kinetics (except F-2 and F-4), exhibited diffusion dominated drug release when data plotted into Korsmeyer Peppas equation. The matrix tablet of naproxen using hydroxypropyl methylcellulose derivatives controls the drug release effectively for 24 h; hence, the formulation can be considered as once daily sustained release tablet of naproxen in order to improve patient compliance.
- Direct compression
- Methocel K15M CR
- Methocel K100M CR
- Naproxen
- Sustained release
How to Cite
References
[2]Lordi NG. Sustained release dosage forms. In:Lachman L, Lieberman HA, Kanig JL, (editors).The theory and practice of industrial pharmacy,3rded. Bombay: Varghese Publishing House,1990; p. 430.
[3]Rosernan TJ, Cardinelli NF. Controlled release technologies. Vol 1. Boca Raton: CRC Press,1983.
[4]The Dow chemical company, formulation for controlled release with METHOCEL cellulose ethers. USA, 1987.
[5]Shah D, Shah Y, Rampradhan M. Development and evaluation of controlled release diltiazem hydrochloride microparticles using cross-linked poly (vinyl alcohol). Drug Dev Ind Pharm1997;23: 567-74.
[6]Rawlins EA. Bentley's text book of pharmaceutics.London: Cassell and Collier MacMillan, 1977.
[7]Aulton ME, Wells TI. Pharmaceutics: The science of dosage form design. London: Churchill Livingstone; 1988.
[8]Martin A. Micromeritics. In: Martin A, (editor).4thed. Physical pharmacy. Baltimore: Lippincott Williams & Wilkins, 2001; pp. 423-54.
[9]Cooper J, Gunn C. Powder flow and compaction.In: Carter SJ, (editor). Tutorial pharmacy. New Delhi: CBS Publishers and Distributors, 1986; pp.211-33.
[10]Hadjiioannou TP, Christian GD, Koupparis MA.Quantitative calculation in pharmaceutical practice and research. New York: VCH Publishers Inc. 1993; pp. 345-8.
[11]Bourne DW. Pharmacokinetics. In: Banker GS ,Rhodes CT, (editors). Modern pharmaceutics.4thed. New York: Marcel Dekker Inc., 2002; pp.67-92.
[12]Higuchi T. Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci1963; 52: 1145-9.
[13]Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I-theoretical consideration. Ind Eng Chem1931; 23: 923-31.
[14]Korsmeyer RW, Gurny R, Doelker E, Buri P,Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm1983;15: 25-35.
[15]Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on HPMC. Adv Drug Deliv Rev2001; 48: 139-57.
[16]Nellore RV, Rekhi GS, Hussain AS, Tillman LG ,Augsbruger LL. Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration.J Control Release1998; 50: 247-56.
[17]Singh B, Ahuja N. Development of controlle-drelease buccoadhesive hydrophilic matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution, and diffusion parameters.Drug Dev Ind Pharm2002; 28: 431-42.
[18]Nafee NA, Ismail FA, Boraie NA, Mortada LM.Mucoadhesive delivery systems. II. Formulation and in-vitro/in-vivoevaluation of buccal mucoadhesive tablets containing water soluble drugs. Drug Dev Ind Pharm2004; 30: 995-1004.
[19] Costa P, Lobo JMS. Modelling and comparison of dissolution profiles. Eur J Pharm Sci2001; 13:123-33.
- Abstract Viewed: 306 times
- IJPS_Volume 5_Issue 4_Pages 215-224 Downloaded: 342 times